论文部分内容阅读
目的:探讨康艾注射液联合化疗治疗晚期肺癌的临床价值。方法:选取2011年8月至2013年8月我院收治的80例晚期肺癌患者为研究对象,将其随机分为对照组和治疗组,对照组40例给予化疗治疗,治疗组40例给予康艾注射液联合化疗治疗,对比两组患者临床治疗效果。结果:对照组有效率为37.5%,治疗组有效率为47.5%,两组对比差异明显,具有统计学意义(P<0.05)。结论:康艾注射液联合化疗治疗晚期肺癌效果确切,意义重大,值得临床推广应用。
Objective: To investigate the clinical value of Kangai injection combined with chemotherapy in the treatment of advanced lung cancer. Methods: Eighty patients with advanced lung cancer who were treated in our hospital from August 2011 to August 2013 were selected as the study subjects. They were randomly divided into control group and treatment group. Forty patients in control group were given chemotherapy, while 40 in treatment group were given Kang Ai injection combined with chemotherapy, compared the clinical efficacy of two groups of patients. Results: The effective rate of the control group was 37.5%, and the effective rate of the treatment group was 47.5%. There was significant difference between the two groups with statistical significance (P <0.05). Conclusion: Kangai injection combined with chemotherapy for advanced lung cancer has definite effect and great significance, which is worthy of clinical application.